American Journal of Psychiatry

Scientific progress in understanding human disease can be measured by the effectiveness of its treatment. Antipsychotic drugs have been proven to alleviate acute psychotic symptoms and prevent their recurrence in schizophrenia, but the outcomes of most ...

https://doi.org/10.1176/appi.ajp.2019.19080865

pdf

abstract

full text

SAVE ARTICLE

Articles

CMEAudio

Cognitive Change in Schizophrenia and Other Psychoses in the Decade Following the First Episode

Publication date: 01 July 2019

Pages811–819

Objective:Schizophrenia is associated with a marked cognitive impairment that is widely believed to remain stable after illness onset. Yet, to date, 10-year prospective studies of cognitive functioning following the first episode with good methodology are ...

https://doi.org/10.1176/appi.ajp.2019.18091088

Altered Cellular White Matter But Not Extracellular Free Water on Diffusion MRI in Individuals at Clinical High Risk for Psychosis

Publication date: 24 June 2019

Pages820–828

Objective:Detecting brain abnormalities in clinical high-risk populations before the onset of psychosis is important for tracking pathological pathways and for identifying possible intervention strategies that may impede or prevent the onset of psychotic ...

https://doi.org/10.1176/appi.ajp.2019.18091044

Video

White Matter in Schizophrenia Treatment Resistance

Publication date: 29 July 2019

Pages829–838

Objective:Failure of antipsychotic medications to resolve symptoms in patients with schizophrenia creates a clinical challenge that is known as treatment resistance. The causes of treatment resistance are unknown, but it is associated with earlier age at ...

https://doi.org/10.1176/appi.ajp.2019.18101212

CMEVideo

Baseline Frontoparietal Task-Related BOLD Activity as a Predictor of Improvement in Clinical Symptoms at 1-Year Follow-Up in Recent-Onset Psychosis

Publication date: 01 July 2019

Pages839–845

Objective:The early course of illness in psychotic disorders is highly variable, and predictive biomarkers of treatment response have been lacking. Trial and error remains the basis for care in early psychosis, and poor outcomes are common. Early ...

https://doi.org/10.1176/appi.ajp.2019.18101126

Penetrance and Pleiotropy of Polygenic Risk Scores for Schizophrenia in 106,160 Patients Across Four Health Care Systems

Publication date: 16 August 2019

Pages846–855

Objective:Individuals at high risk for schizophrenia may benefit from early intervention, but few validated risk predictors are available. Genetic profiling is one approach to risk stratification that has been extensively validated in research cohorts. ...

https://doi.org/10.1176/appi.ajp.2019.18091085